CN110467596A - 四氢萘基脲衍生物的晶体 - Google Patents

四氢萘基脲衍生物的晶体 Download PDF

Info

Publication number
CN110467596A
CN110467596A CN201810448130.XA CN201810448130A CN110467596A CN 110467596 A CN110467596 A CN 110467596A CN 201810448130 A CN201810448130 A CN 201810448130A CN 110467596 A CN110467596 A CN 110467596A
Authority
CN
China
Prior art keywords
base
methyl
crystal
type crystal
phenylpyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810448130.XA
Other languages
English (en)
Chinese (zh)
Inventor
刘娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Co Ltd
Mochida Pharmaceutical Co Ltd
Original Assignee
Mochida Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Co Ltd filed Critical Mochida Co Ltd
Priority to CN201810448130.XA priority Critical patent/CN110467596A/zh
Priority to PCT/JP2018/022041 priority patent/WO2019215937A1/ja
Publication of CN110467596A publication Critical patent/CN110467596A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201810448130.XA 2018-05-11 2018-05-11 四氢萘基脲衍生物的晶体 Pending CN110467596A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201810448130.XA CN110467596A (zh) 2018-05-11 2018-05-11 四氢萘基脲衍生物的晶体
PCT/JP2018/022041 WO2019215937A1 (ja) 2018-05-11 2018-06-08 テトラヒドロナフチルウレア誘導体の結晶

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810448130.XA CN110467596A (zh) 2018-05-11 2018-05-11 四氢萘基脲衍生物的晶体

Publications (1)

Publication Number Publication Date
CN110467596A true CN110467596A (zh) 2019-11-19

Family

ID=68467900

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810448130.XA Pending CN110467596A (zh) 2018-05-11 2018-05-11 四氢萘基脲衍生物的晶体

Country Status (2)

Country Link
CN (1) CN110467596A (ja)
WO (1) WO2019215937A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11325895B2 (en) * 2017-09-15 2022-05-10 Mochida Pharmaceutical Co., Ltd. Crystals of tetrahydronaphthyl urea derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07101940A (ja) * 1993-08-13 1995-04-18 Nippon Nohyaku Co Ltd ピリミジンおよびピリジン誘導体、その製法および用途
WO2014078325A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
HUE031557T2 (en) * 2012-11-13 2017-07-28 Array Biopharma Inc Bicyclic urea, thiourea, guanidine, and cyanoguadinine compounds used to treat pain
WO2015039333A1 (en) * 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Also Published As

Publication number Publication date
WO2019215937A1 (ja) 2019-11-14

Similar Documents

Publication Publication Date Title
CN106029614B (zh) 化合物的组合物及其用途
CN102421784B (zh) 作为gsk-3抑制剂的7-环烷基氨基喹诺酮
UA125559C2 (uk) Композиції інгібітора lsd1
JP7148500B2 (ja) 新規テトラヒドロナフチルウレア誘導体
TW201605847A (zh) 雜環化合物
CN105073768A (zh) Ras抑制剂及其用途
CN102470127A (zh) 联芳基化合物和其使用方法
CN105461736B (zh) 具有锌结合位的磷脂酰肌醇3-激酶抑制剂
CN108779073A (zh) 用于治疗癌症的组合物和方法
JP6155026B2 (ja) プロテインキナーゼ阻害のための新規化合物及びその治療的使用
CN109475559A (zh) 抑制pi3k的新型喹唑啉酮衍生物及含其的药物组合物
CN110461838A (zh) 噁二唑瞬时受体电位通道抑制剂
CN106565685B (zh) 微管蛋白抑制剂
CN109843868A (zh) Olig2活性的抑制
CN104230912B (zh) 喹啉衍生物、其制备方法及其用途
CN104557909B (zh) 3-酰氧基取代右旋去氧娃儿藤宁衍生物、其制法和药物组合物与用途
CN110467596A (zh) 四氢萘基脲衍生物的晶体
CN105777520A (zh) 一种新型查尔酮化合物Chalcone-1203及其组合物、制备方法和应用
CN104402861A (zh) 苯磺酰胺衍生物、制备方法及治疗用途
JP7134983B2 (ja) テトラヒドロナフチルウレア誘導体の結晶
CN108586485A (zh) 1-(4-羟亚胺基噻吩并[2,3-b]噻喃甲酰基)哌嗪类化合物及其应用
CN108822127A (zh) 4-羟亚胺基噻吩并[2,3-b]噻喃-2-甲酰胺类化合物及其用途
CN108586484A (zh) 噻吩并噻喃甲酰胺类化合物及其应用
CN108822125A (zh) 1-(噻吩并[2,3-b]噻喃甲酰基)-4-脂肪烃基哌嗪类化合物及其医药用途
WO2015158067A1 (zh) 吡唑并嘧啶酮化合物以及衍生物、及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191119

WD01 Invention patent application deemed withdrawn after publication